WiCON | Pharma China (Web Edition)

ONLINE ENQUIRY

WiCON International Group
Bellevue, WA 98007, USA
info@pharmachinaonline.com

WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com

High Return Rate: Are Chinese Innovative Drugs Facing a "Breakup" Crisis in Ov... Analysis of Booming License-Out Deals Reveals a Concerning Trend of Terminated Collaborations for Chinese Pharmaceutical Companies, according to a recent feature article ...
(4/29/2025)

US Tariffs on Pharmaceuticals Could Hit Chines... (5/16/2025)

SMEI: China's Pharmaceutical Industry Seeks St... (5/16/2025)

Trump's Drug Pricing and the US-China Trade De... (5/12/2025)

China Still Go-To Source for New Drugs Despite... (5/9/2025)

Redefining Translational Research and China's ... (5/8/2025)

China Introduces A New Regulatory Data Protect... (5/5/2025)

Pharma's Crossroads: U.S. Investment Surges Un... (5/1/2025)

High Return Rate: Are Chinese Innovative Drugs... (4/29/2025)

China Aims for Significant Pharma Industry Dig... (4/26/2025)

MNC Pharma's Q1/2025 China Performance: Diverg... (4/25/2025)

Cell Therapy to AI: How J&J Has Been Sourcing ... (4/25/2025)

China Biopharma Tracker – March 2025 (PharmaD... (4/24/2025)

WuXi Biologics Offloads German Plant to ... (5/16/2025) Viva Biotech Unveils Proprietary AI Plat... (5/16/2025) Nuance Pharma Reports Positive Phase 3 R... (5/16/2025) US Push to Decouple from China May Spike... (5/16/2025) NMPA Orders Package Insert/Label Update ... (5/16/2025) NMPA Approves CANbridge's Velaglucerase ... (5/16/2025) China Approves Xuanzhu Bio's Birociclib ... (5/16/2025) CSPC and Cipla Forge Exclusive U.S. Lice... (5/16/2025) China Approves Haisco Pharma's Anrikefon... (5/16/2025) ArkBio Reports Positive Mid-Stage Result... (5/16/2025) Hengrui Aims to Raise $1.27B in Hong Kon... (5/15/2025) NMPA Approves Novartis' Scemblix for Fir... (5/15/2025) Novartis Gains NMPA Approval for Expande... (5/15/2025) Chinese Drugmakers May Weather Trump's T... (5/14/2025) CDE Issues the List of Reference Formula... (5/14/2025) R&D Spending Rises at 276 Chinese Drugma... (5/14/2025) Six Drugs Granted Priority Review as Chi... (5/14/2025) Beigene Submits New Indication Applicati... (5/14/2025)

China's Hospital Drug Market Shows Slight Growth in 202... China Unveils Ambitious Plan to Boost Health-Related Co... Chinese VMS OTC Market Growth Slowed to 2.7% in 2024 Newish Tech Secures Series B Financing to Advance Next-... China's Retail Pharmacy Market Reaches CNY 574 Billion ...

ArkBio Reports Positive Mid-Stage Results for Anti-Fibr... CSPC and Cipla Forge Exclusive U.S. Licensing Deal for ... US Push to Decouple from China May Spike Drug Costs, Ex... Viva Biotech Unveils Proprietary AI Platform to Reshape... WuXi Biologics Offloads German Plant to Terumo, Refocus...

NMPA Orders Package Insert/Label Update for Ranitidine ... Six Drugs Granted Priority Review as China Registers Ov... CDE Issues the List of Reference Formulations for GQCE ... CDE Publicizes the List of Reference Formulations for G... CDE Seeks Comments on Draft Guidelines for Subject Sele...

China Expands Geriatric Services at Major Hospitals as ... China's BMI Fund Reports Big Surplus in Q1/2025 China's Public Hospitals Grapple with Mounting Debt Ami... Dementia Cases Surge in China at an Unprecedented Rate NHC Ministers Meet with Top Pharma MNC Executives

AstraZeneca Faces Escalating Legal Challenges in China ... BeiGene Secures Key Patent Victory in Brukinsa Dispute ... State Council Approves Draft Medical Security Law, Stre... Novo Nordisk Sues KBP Biosciences for $830 Million Over... State Council Releases Final Antitrust Guidelines for t...

FDA Issues Warning Letters to Two Chinese API Manufactu... Implications of China's Growing Influence in Global Pha... FDA Issues Warning to Tianjin Darentang for Manufacturi... Shanghai Pharma Considers API Partnerships with Indian ... Aurobindo Challenges China in the Global Penicillin G M...

China Approves Haisco Pharma's Anrikefon (HSK21542) for... China Approves Xuanzhu Bio's Birociclib for HR+/HER2- A... NMPA Approves CANbridge's Velaglucerase Beta for Gauche... Nuance Pharma Reports Positive Phase 3 Results for Ensi... Novartis Gains NMPA Approval for Expanded Use of Kisqal...

BioAtla and BeiGene Revise Global Deal for Novel Condit... Pfizer to Absorb Mylan, Creating Global Generic Powerho... PhRMA Calls for Trade Deals That Force Countries to Pay... IQVIA: Global Pharma to Grow Slower in the Next Five Ye... Pfizer and GSK Announce JV to Create a Global Consumer ...

Recent Executive Moves Recent Executive Moves Recent Executive Moves Recent Executive Moves Recent Executive Moves

China Introduces Plan for Pudong New Area's Pilot Compr... Upcoming Event: 2023 Pharma CI USA Conference & Exhibit... Upcoming Event: 15th Annual Pharma Market Research Conf... Upcoming Event: 6th International Conference on Emergin... Upcoming Event: PHARM Connect Congress

Pharma China is the most influential English media and source of business intelligence covering the Chinese pharmaceutical and biopharmaceutical sector...

WiCON has been helping international healthcare companies succeed in China and other Asian markets since 1991. We advise our clients on every stage of their China and Asian business. We worked with clients in many regions of the world...

2023 Order Form + Product Descripti... WiCON Publishes the China Pharmaceu... WiCON Publishes the China Pharmaceu... WiCON Publishes the China Pharmaceu... WiCON Publishes the China Pharmaceu...